Agilent: FDA Approves Teva's Content Uniformity Method Using TRS100 System
July 05 2022 - 08:56AM
Dow Jones News
By Will Feuer
Agilent Technologies Inc. said the Food and Drug Administration
has approved Teva Pharmaceutical Industries Ltd.'s content
uniformity method using Agilent's TRS100 Raman quantitative
pharmaceutical analysis system.
Agilent said its TRS100 system helps measure how much active
pharmaceutical ingredient is inside a tablet or capsule, and
whether the amount is uniform across a batch.
"It is a substantial investment to change manufacturing and QC
processes, and an FDA approval minimizes the perceived risk of
adopting this new technology," said Geoff Winkett, Agilent vice
president of molecular spectroscopy.
The FDA's approval of the TRS100 method for content uniformity
testing by Teva is a key milestone for the product, Mr. Winkett
said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
July 05, 2022 08:41 ET (12:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2023 to Mar 2024